Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non–small cell lung cancer

키워드

참고문헌 (90)

1. Kim HC, "Clinical characteristics and prognostic factors of lung cancer in Korea : a pilot study of data from the Korean Nationwide Lung Cancer Registry", Tuberc Respir Dis (Seoul), 82, pp.118~125 (2019)
2. Vital Statistics Division, "Cause-of-death statistics in 2018 in the Republic of Korea", J Korean Med Assoc, 63, pp.286~297 (2020)
3. Alexander M, "Update 2020 : management of non-small cell lung cancer", Lung, 198, pp.897~907 (2020)
4. Lee GW, "Current advances in the treatment of lung cancer with immune checkpoint inhibitors", J Korean Med Assoc, 64, pp.333~341 (2021)
5. Anagnostou VK, "Cancer immunotherapy : a future paradigm shift in the treatment of non-small cell lung cancer", Clin Cancer Res, 21, pp.976~984 (2015)
6. Mamdani H, "Immunotherapy in lung cancer : current landscape and future directions", Front Immunol, 13, pp.823618~ (2022)
7. Pardoll DM, "The blockade of immune checkpoints in cancer immunotherapy", Nat Rev Cancer, 12, pp.252~264 (2012)
8. Ettinger DS, "Non-small cell lung cancer, version 3. 2022, NCCN Clinical Practice Guidelines in Oncology", J Natl Compr Canc Netw, 20, pp.497~530 (2022)
9. Camidge DR, "Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC", Nat Rev Clin Oncol, 16, pp.341~355 (2019)
10. Suresh K, "Immune checkpoint immunotherapy for non-small cell lung cancer : benefits and pulmonary toxicities", Chest, 154, pp.1416~1423 (2018)
11. Bai R, "Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors", Biomark Res, 8, pp.34~ (2020)
12. Uruga H, "Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer : PD-L1 and beyond", Virchows Arch, 478, pp.31~44 (2021)
13. Pabst L, "Prognostic and predictive biomarkers in the era of immunotherapy for lung cancer", Int J Mol Sci, 24, pp.7577~ (2023)
14. Kim H, "PD-L1 testing in non-small cell lung cancer : past, present, and future", J Pathol Transl Med, 53, pp.199~206 (2019)
15. Ullah A, "PD-L1 over-expression varies in different subtypes of lung cancer : will this affect future therapies?", Clin Pract, 12, pp.653~671 (2022)
16. Domblides C, "Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma", J Thorac Oncol, 15, pp.860~866 (2020)
17. Sharma J, "P2. 01-056 Distinct PD-L1 expression in different components of pulmonary sarcomatoid carcinoma and its association with MET mutation. Topic : immune mechanisms in thoracic cancer and targeted therapy", J Thoracic Oncol, 12(1 Suppl), pp.S819~S820 (2017)
18. Brueckl WM, "Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor(ICI)therapy in non-small cell lung cancer(NSCLC)", BMC Cancer, 20, pp.1185~ (2020)
19. Li H, "Biomarkers of response to PD-1 pathway blockade", Br J Cancer, 126, pp.1663~1675 (2022)
20. Gettinger S, "Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer", J Clin Oncol, 34, pp.2980~2987 (2016)
21. Yi M, "Biomarkers for predicting efficacy of PD-1", PD-L1 inhibitors, 2018, pp.17, 129~
22. Hirsch FR, "PD-L1 immunohistochemistry assays for lung cancer : results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project", J Thorac Oncol, 12, pp.208~222 (2017)
23. Choi S, "Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response", Eur J Cancer, 170, pp.17~26 (2022)
24. Tumeh PC, "PD-1 blockade induces responses by inhibiting adaptive immune resistance", Nature, 515, pp.568~571 (2014)
25. Greten FR, "Inflammation and cancer : triggers, mechanisms, and consequences", Immunity, 51, pp.27~41 (2019)
26. Fridman WH, "The immune contexture in human tumours : impact on clinical outcome", Nat Rev Cancer, 12, pp.298~306 (2012)
27. Liu X, "Rethinking immune checkpoint blockade : ‘beyond the T cell’", J Immunother Cancer, 9, pp.e001460~ (2021)
28. El Bairi K, "The tale of TILs in breast cancer : a report from The International Immuno-Oncology Biomarker Working Group", NPJ Breast Cancer, 7, pp.150~ (2021)
29. Aaltomaa S, "Lymphocyte infiltrates as a prognostic variable in female breast cancer", Eur J Cancer, 28A, pp.859~864 (1992)
30. Luen SJ, "Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer", Pathology, 49, pp.141~155 (2017)
31. Denkert C, "Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer", J Clin Oncol, 28, pp.105~113 (2010)
32. Salgado R, "The evaluation of tumorinfiltrating lymphocytes(TILs)in breast cancer : recommendations by an International TILs Working Group 2014", Ann Oncol, 26, pp.259~271 (2015)
33. Fuchs TL, "Assessment of tumor-infiltrating lymphocytes using International TILs Working Group(ITWG)system is a strong predictor of overall survival in colorectal carcinoma : a study of 1034 patients", Am J Surg Pathol, 44, pp.536~544 (2020)
34. Ahn SG, "Current issues and clinical evidence in tumor-infiltrating lymphocytes in breast cancer", J Pathol Transl Med, 49, pp.355~363 (2015)
35. Ali HR, "Association between CD8+ T-cell infiltration and breast cancer survival in 12, 439 patients", Ann Oncol, 25, pp.1536~1543 (2014)
36. Raskov H, "Cytotoxic CD8(+)T cells in cancer and cancer immunotherapy", Br J Cancer, 124, pp.359~367 (2021)
37. Speiser DE, "CD4(+)T cells in cancer", Nat Cancer, 4, pp.317~329 (2023)
38. Tay RE, "Revisiting the role of CD4(+)T cells in cancer immunotherapy : new insights into old paradigms", Cancer Gene Ther, 28, pp.5~17 (2021)
39. Gataa I, "Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy", Eur J Cancer, 145, pp.221~229 (2021)
40. Lopez de Rodas M, "Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer", J Immunother Cancer, 10, pp.e004440~ (2022)
41. Teng MW, "Classifying cancers based on T-cell infiltration and PD-L1", Cancer Res, 75, pp.2139~2145 (2015)
42. Jiang Z, "A combination of biomarkers predict response to immune checkpoint blockade therapy in non-small cell lung cancer", Front Immunol, 12, pp.813331~ (2021)
43. Deutsch JS, "Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma", Cell Rep Med, 4, pp.100947~ (2023)
44. Swisher SK, "Interobserver agreement between pathologists assessing tumor-infiltrating lymphocytes(TILs)in breast cancer using methodology proposed by the International TILs Working Group", Ann Surg Oncol, 23, pp.2242~2248 (2016)
45. Chen DS, "Elements of cancer immunity and the cancerimmune set point", Nature, 541, pp.321~330 (2017)
46. Park S, "Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non-small-cell lung cancer", J Clin Oncol, 40, pp.1916~1928 (2022)
47. Backman M, "Spatial immunophenotyping of the tumour microenvironment in non-small cell lung cancer", Eur J Cancer, 185, pp.40~52 (2023)
48. Sautes-Fridman C, "Tertiary lymphoid structures in the era of cancer immunotherapy", Nat Rev Cancer, 19, pp.307~325 (2019)
49. Colbeck EJ, "Tertiary lymphoid structures in cancer : drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease?", Front Immunol, 8, pp.1830~ (2017)
50. Trub M, "Tertiary lymphoid structures as a predictive biomarker of response to cancer immunotherapies", Front Immunol, 12, pp.674565~ (2021)
51. Zhang Q, "Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response", Front Immunol, 13, pp.1063711~ (2022)
52. Helmink BA, "B cells and tertiary lymphoid structures promote immunotherapy response", Nature, 577, pp.549~555 (2020)
53. Sautes-Fridman C, "Tertiary lymphoid structures and B cells : clinical impact and therapeutic modulation in cancer", Semin Immunol, 48, pp.101406~ (2020)
54. Fridman WH, "B cells and cancer : to B or not to B?", J Exp Med, 218, pp.e20200851~ (2021)
55. Silina K, "Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures : a novel anti-cancer treatment avenue?", Cancer Immunol Immunother, 63, pp.643~662 (2014)
56. Rakaee M, "Tertiary lymphoid structure score : a promising approach to refine the TNM staging in resected non-small cell lung cancer", Br J Cancer, 124, pp.1680~1689 (2021)
57. Blanchard L, "High endothelial venules(HEVs)in immunity, inflammation and cancer", Angiogenesis, 24, pp.719~753 (2021)
58. Hong SA, "High endothelial venule with concomitant high CD8+ tumor-infiltrating lymphocytes is associated with a favorable prognosis in resected gastric cancer", J Clin Med, 9, pp.2628~ (2020)
59. Fang J, "Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment : new insights and therapeutic implications", Cell Death Dis, 14, pp.586~ (2023)
60. Milutinovic S, "The dual role of high endothelial venules in cancer progression versus immunity", Trends Cancer, 7, pp.214~225 (2021)
61. Allen E, "Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation", Sci Transl Med, 9, pp.eaak9679~ (2017)
62. Ye D, "High endothelial venules predict response to PD-1 inhibitors combined with anti-angiogenesis therapy in NSCLC", Sci Rep, 13, pp.16468~ (2023)
63. Hussain B, "High endothelial venules as potential gateways for therapeutics", Trends Immunol, 43, pp.728~740 (2022)
64. Hazini A, "Deregulation of HLA-I in cancer and its central importance for immunotherapy", J Immunother Cancer, 9, pp.e002899~ (2021)
65. Pagliuca S, "Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond", Front Immunol, 13, pp.944872~ (2022)
66. Wang C, "Human leukocyte antigen(HLA)and cancer immunotherapy : HLA-dependent and-independent adoptive immunotherapies", Ann Blood, 5, pp.14~ (2020)
67. Chowell D, "Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy", Science, 359, pp.582~587 (2018)
68. Wang H, "Beta2-microglobulin(B2M)in cancer immunotherapies : Biological function, resistance and remedy", Cancer Lett, 517, pp.96~104 (2021)
69. Gavrielatou N, "Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma", Cancer Res Commun, 3, pp.558~563 (2023)
70. Sade-Feldman M, "Resistance to checkpoint blockade therapy through inactivation of antigen presentation", Nat Commun, 8, pp.1136~ (2017)
71. Lechner MG, "Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy", J Immunother, 36, pp.477~489 (2013)
72. Sabbatino F, "Role of human leukocyte antigen system as a predictive biomarker for checkpoint-based immunotherapy in cancer patients", Int J Mol Sci, 21, pp.7295~ (2020)
73. Ashizawa T, "Antitumor effect of programmed death-1(PD-1)blockade in humanized the NOG-MHC double knockout mouse", Clin Cancer Res, 23, pp.149~158 (2017)
74. Ladanyi A, "HLA class I downregulation in progressing metastases of melanoma patients treated with ipilimumab", Pathol Oncol Res, 28, pp.1610297~ (2022)
75. Pescia C, "TIGIT in lung cancer : potential theranostic implications", Life (Basel), 13, pp.1050~ (2023)
76. Yang Z, "PVR", TIGIT and PD-L1, Transl Oncol, pp.2022, 24[DOI]
77. Kim SW, "Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma", Mod Pathol, 34, pp.141~160 (2021)
78. Aggarwal V, "LAG-3 as the third checkpoint inhibitor", Nat Immunol, 24, pp.1415~1422 (2023)
79. Sauer N, "LAG-3 as a potent target for novel anticancer therapies of a wide range of tumors", Int J Mol Sci, 23, pp.9958~ (2022)
80. He Y, "LAG-3 protein expression in nonsmall cell lung cancer and its relationship with PD-1", PD-L1 and tumor-infiltrating lymphocytes, 2017, pp.12, 814~823
81. Borgeaud M, "Novel targets for immunecheckpoint inhibition in cancer", Cancer Treat Rev, 120, pp.102614~ (2023)
82. Inoue Y, "Prognostic impact of CD73and A2A adenosine receptor expression in non-small-cell lung cancer", Oncotarget, 8, pp.8738~8751 (2017)
83. Loi S, "CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer", Proc Natl Acad Sci U S A, 110, pp.11091~11096 (2013)
84. Wu XR, "High expression of CD73 as a poor prognostic biomarker in human colorectal cancer", J Surg Oncol, 106, pp.130~137 (2012)
85. Rocha P, "CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma", Cancer Immunol Immunother, 70, pp.1965~1976 (2021)
86. Bendell JC, "Safety and efficacy of the anti-CD73 monoclonal antibody(mAb)oleclumab ± durvalumab in patients(pts)with advanced colorectal cancer(CRC), pancreatic ductal adenocarcinoma(PDAC), or EGFR-mutant non-small cell lung cancer(EGFRm NSCLC)", J Clin Oncol, 39, pp.9047~ (2021)
87. Jin D, "CD73 on tumor cells impairs antitumor T-cell responses : a novel mechanism of tumor-induced immune suppression", Cancer Res, 70, pp.2245~2255 (2010)
88. Ohta A, "A2A adenosine receptor protects tumors from antitumor T cells", Proc Natl Acad Sci U S A, 103, pp.13132~13137 (2006)
89. Ishii H, "Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC", Thorac Cancer, 11, pp.950~955 (2020)
90. Lee JB, "Clinical insights into novel immune checkpoint inhibitors", Front Pharmacol, 12, pp.681320~ (2021)

관련 논문AI추천